A tipping point in drug dosing in late-life schizophrenia

Current Psychiatry Reports

Volumn 13, Issue 3, 2011, Pages 225-233

  Tsuboi, Takashi ^a,b   Suzuki, Takefumi ^a,c,d   Uchida, Hiroyuki ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAISEIKAI CENTRAL HOSPITAL   (Japan)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

Aging; Antipsychotics; Geriatrics; Schizophrenia; Sensitivity

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; RIVASTIGMINE;

AGING; AGITATION; ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; COGNITIVE DEFECT; DELUSION; DELUSIONAL DISORDER; DEMENTIA; DRUG SAFETY; DYSTONIA; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; HALLUCINATION; HUMAN; MULTIINFARCT DEMENTIA; OPTIMAL DRUG DOSE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RECEPTOR OCCUPANCY; RECOMMENDED DRUG DOSE; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

AGE FACTORS; ANTIPSYCHOTIC AGENTS; HUMANS; POLYPHARMACY; SCHIZOPHRENIA;

EID: 79955894406     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-011-0189-z     Document Type: Review

References (69)

1. Uchida H, Suzuki T, Mamo DC, et al. Effects of age and age of onset on prescribed antipsychotic dose in schizophrenia spectrum disorders: a survey of 1, 418 patients in Japan. Am J Geriatr Psychiatry. 2008;16:584-93.
2. Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360:225-35.
3. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934-43. (Pubitemid 41464695)
4. Uchida H, Mamo DC. Dosing of antipsychotics in schizophrenia across the life-spectrum. Prog Neuro psychopharmacol Biol Psychiatry. 2009;33:917-20.
5. Kane JM, Leucht S, Carpenter D, et al. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry. 2003;64 Suppl 12:5-19.
6. Haro JM, Novick D, Suarez D, et al. Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol. 2006;26:571-8. (Pubitemid 44772733)
7. Lieberman JA. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. J Clin Psychiatry. 2007;68:e04.
8. Kane JM, Rifkin A, Woerner M, et al. Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Arch Gen Psychiatry. 1983;40:893-6.
9. Alexopoulos GS, Streim J, Carpenter D, et al. Using antipsychotic agents in older patients. J Clin Psychiatry. 2004;65 Suppl 2:5-99.
10. Falkai P, Wobrock T, Lieberman J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry. 2005;6:132-91.
11. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161:1-56.
12. Sernyak MJ, Dausey D, Desai R, et al. Prescribers' nonadherence to treatment guidelines for schizophrenia when prescribing neuroleptics. Psychiatr Serv. 2003;54:246-8. (Pubitemid 36752858)
13. Leslie DL, Rosenheck RA. Adherence of schizophrenia pharmacotherapy to published treatment recommendations: patient, facility, and provider predictors. Schizophr Bull. 2004;30:649-58. (Pubitemid 39625708)
14. Chen RS, Nadkarni PM, Levin FL, et al. Using a computer database to monitor compliance with pharmacotherapeutic guidelines for schizophrenia. Psychiatr Serv. 2000;51:791-4. (Pubitemid 30354234)
15. Jeste DV, Lacro JP, Gilbert PL, et al. Treatment of late-life schizophrenia with neuroleptics. Schizophr Bull. 1993;19:817-30. (Pubitemid 23339438)
16. Mamo DC, Sweet RA, Chengappa KN, et al. The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders. Int J Geriatr Psychiatry. 2002;17:1012-7. (Pubitemid 35363420)
17. Ayd Jr FJ. A survey of drug-induced extrapyramidal reactions. JAMA. 1961;175:1054-60.
18. Caligiuri MP, Lacro JP, Jeste DV. Incidence and predictors of drug-induced parkinsonism in older psychiatric patients treated with very low doses of neuroleptics. J Clin Psychopharmacol. 1999;19:322-8. (Pubitemid 29344845)
19. Jabs BE, Bartsch AJ, Pfuhlmann B. Susceptibility to neuroleptic-induced parkinsonism-age and increased substantia nigra echogenicity as putative risk factors. Eur Psychiatry. 2003;18:177-81. (Pubitemid 36745203)
20. Jeste DV. Tardive dyskinesia rates with atypical antipsychotics in older adults. J Clin Psychiatry. 2004;65 Suppl 9:21-4.
21. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161:414-25. (Pubitemid 38326094)
22. Jeste DV, Okamoto A, Napolitano J, et al. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry. 2000;157:1150-5. (Pubitemid 30432498)
23. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol. 1988;8:52S-6.
24. Sachdev P, Kruk J. Clinical characteristics and predisposing factors in acute drug-induced akathisia. Arch Gen Psychiatry. 1994;51:963-74. (Pubitemid 24371866)
25. Addonizio G, Alexopoulos GS. Drug-induced dystonia in young and elderly patients. Am J Psychiatry. 1988;145:869-71.
26. Lemmens P, Brecher M, Van Baelen B. A combined analysis of double-blind studies with risperidone vs. placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. Acta Psychiatr Scand. 1999;99:160-70. (Pubitemid 29118258)
27. Uchida H, Rajji TK, Mulsant BH, et al. D2 receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia. J Clin Psychopharmacol. 2009;29:571-5.
28. Ballard C, Margallo-Lana M, Juszczak E, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ. 2005;330:874.
29. Brodaty H, Ames D, Snowdon J, et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry. 2003;64:134-43. (Pubitemid 36268315)
30. Chan WC, Lam LC, Choy CN, et al. A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients. Int J Geriatr Psychiatry. 2001;16:1156-62. (Pubitemid 34044183)
31. Clark WS, Street JS, Feldman PD, et al. The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease. J Clin Psychiatry. 2001;62:34-40. (Pubitemid 32154316)
32. De Deyn P, Jeste DV, Swanink R, et al. Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study. J Clin Psychopharmacol. 2005;25:463-7. (Pubitemid 41368369)
33. De Deyn PP, Carrasco MM, Deberdt W, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry. 2004;19:115-26. (Pubitemid 38247846)
34. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology. 1999;53:946-55. (Pubitemid 29442108)
35. Deberdt WG, Dysken MW, Rappaport SA, et al. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia. Am J Geriatr Psychiatry. 2005;13:722-30. (Pubitemid 41197244)
36. Fontaine CS, Hynan LS, Koch K, et al. A double-blind comparison of olanzapine versus risperidone in the acute treatment of dementia-related behavioral disturbances in extended care facilities. J Clin Psychiatry. 2003;64:726-30. (Pubitemid 36750153)
37. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry. 1999;60:107-15. (Pubitemid 29104387)
38. Mintzer J, Greenspan A, Caers I, et al. Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial. Am J Geriatr Psychiatry. 2006;14:280-91.
39. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14:191-210.
40. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry. 2000;57:968-76.
41. Tariot PN, Schneider L, Katz IR, et al. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry. 2006;14:767-76. (Pubitemid 44380069)
42. Howanitz E, Pardo M, Smelson DA, et al. The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia. J Clin Psychiatry. 1999;60:41-4. (Pubitemid 29069885)
43. Jeste DV, Barak Y, Madhusoodanan S, et al. International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry. 2003;11:638-47. (Pubitemid 37392328)
44. Kennedy JS, Jeste D, Kaiser CJ, et al. Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial. Int J Geriatr Psychiatry. 2003;18:1013-20. (Pubitemid 37479374)
45. Sproule BA, Lake J, Mamo DC, et al. Are antipsychotic prescribing patterns different in older and younger adults?: a survey of 1357 psychiatric inpatients in Toronto. Can J Psychiatry. 2010;55:248-54.
46. Uchida H, Mamo DC, Mulsant BH, et al. Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms. J Clin Psychiatry. 2009;70:397-405. This article reviews the literature on the increased sensitivity to antipsychotic drugs in older adults and discusses potential mechanisms underlying this phenomenon..
47. Bigos KL, Pollock BG, Coley KC, et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol. 2008;48:157-65.
48. Ng W, Uchida H, Ismail Z, et al. Clozapine exposure and the impact of smoking and gender: a population pharmacokinetic study. Ther Drug Monit. 2009;31:360-6.
49. Mauri MC, Volonteri LS, Colasanti A, et al. Clinical pharmaco-kinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet. 2007;46:359-88. (Pubitemid 46686464)
50. Young A. Ageing and physiological functions. Philos Trans R Soc Lond B Biol Sci. 1997;352:1837-43. (Pubitemid 28056270)
51. Cadieux RJ. Drug interactions in the elderly. How multiple drug use increases risk exponentially. Postgrad Med. 1989;86:179-86.
52. Toornvliet R, van Berckel BN, Luurtsema G, et al. Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography. Clin Pharmacol Ther. 2006;79:540-8.
53. Antonini A, Leenders KL, Reist H, et al. Effect of age on D2 dopamine receptors in normal human brain measured by positron emission tomography and 11 C-raclopride. Arch Neurol. 1993;50:474-80. (Pubitemid 23143137)
54. Ichise M, Ballinger JR, Tanaka F, et al. Age-related changes in D2 receptor binding with iodine-123-iodobenzofuran SPECT. J Nucl Med. 1998;39:1511-8.
55. Wong DF, Wagner Jr HN, Dannals RF, et al. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science. 1984;226:1393-6. (Pubitemid 15161272)
56. Uchida H, Kapur S, Mulsant BH, et al. Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms. Am J Geriatr Psychiatry. 2009;17:255-63.
57. Lacro JP, Jeste DV. Physical comorbidity and polypharmacy in older psychiatric patients. Biol Psychiatry. 1994;36:146-52. (Pubitemid 24269142)
58. Uchida H, Suzuki T, Mamo DC, et al. Benzodiazepine and antidepressant use in elderly patients with anxiety disorders: a survey of 796 outpatients in Japan. J Anxiety Disord. 2009;23:477-81.
59. Uchida H, Suzuki T, Mamo DC, et al. Survey of benzodiazepine and antidepressant use in outpatients with mood disorders in Japan. Psychiatry Clin Neurosci. 2009;63:244-6.
60. Angus WR, Romney DM. The effect of diazepam on patients' memory. J Clin Psychopharmacol. 1984;4:203-6. (Pubitemid 14061178)
61. Swift CG, Swift MR, Hamley J, et al. Side-effect 'tolerance' in elderly long-term recipients of benzodiazepine hypnotics. Age Ageing. 1984;13:335-43.
62. Tsunoda K, Uchida H, Suzuki T, et al. Effects of discontinuing benzodiazepine-derivative hypnotics on postural sway and cognitive functions in the elderly. Int J Geriatr Psychiatry. 2009;25:1259-65.
63. Nurmi-Luthje I, Kaukonen JP, Luthje P, et al. Use of benzodiazepines and benzodiazepine-related drugs among 223 patients with an acute hip fracture in Finland: comparison of benzodiazepine findings in medical records and laboratory assays. Drugs Aging. 2006;23:27-37. (Pubitemid 43290882)
64. Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003;163:2716-24. (Pubitemid 37517412)
65. Hori H, Noguchi H, Hashimoto R, et al. Antipsychotic medication and cognitive function in schizophrenia. Schizophr Res. 2006;86:138-46. (Pubitemid 44234045)
66. Hughes AM, Lynch P, Rhodes J, et al. Electroencephalographic and psychomotor effects of chlorpromazine and risperidone relative to placebo in normal healthy volunteers. Brit J Clin Pharmacol. 1999;48:323-30. (Pubitemid 29417714)
67. Morrens M, Wezenberg E, Verkes RJ, et al. Psychomotor and memory effects of haloperidol, olanzapine, and paroxetine in healthy subjects after short-term administration. J Clin Psychopharmacol. 2007;27:15-21. (Pubitemid 46105758)
68. Minzenberg MJ, Poole JH, Benton C, et al. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry. 2004;161:116-24. (Pubitemid 38419316)
69. Uchida H, Pollock BG, Bies RR, et al. Predicting age-specific dosing of antipsychotics. Clin Pharmacol Ther. 2009;86:360-2. This article discusses potential advantages of combining population pharmacokinetic techniques and brain imaging with the goal of establishing a model for the prediction of age-specific dosing of antipsychotic drugs for patients with schizophrenia..